Arrowhead Pharmaceuticals, Inc. (ARWR): who owns it and who trades it
As of Nov 16, 2026, ARWR insiders reported 64 open-market sales worth $37.3M and no purchases in the last 12 months, with 45% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christopher Richard Anzalone (CEO), with $24M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Arrowhead Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ARWR
498 funds and institutions reported ARWR shares worth $9.8B at the end of Q2 2026, about 85% of the company. The largest holder is BlackRock, Inc. with 10.5%.
Funds and institutions (13F) 85%Everyone else 15%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 14.83M | 10.53% | $1.2B | -18% |
| Avoro Capital Advisors LLC | 11.36M | 8.06% | $926M | +6% |
| FMR LLC (Fidelity) | 8.04M | 5.71% | $655M | +11% |
| Vanguard Portfolio Management LLC | 6.35M | 4.51% | $518M | -11% |
| Vanguard Capital Management LLC | 6.11M | 4.34% | $498M | +1% |
| State Street Corp | 5.69M | 4.04% | $464M | -12% |
| Norges Bank | 3.90M | 2.77% | $318M | – |
| Invesco Ltd. | 3.88M | 2.76% | $317M | +18% |
| Geode Capital Management, LLC | 3.53M | 2.51% | $299M | -17% |
| Fred Alger Management, LLC | 3.30M | 2.34% | $269M | -1% |
| Baker Bros. Advisors LP | 1.99M | 1.41% | $162M | No change |
| Siren, L.L.C. | 1.72M | 1.22% | $140M | +6% |
| Vestal Point Capital, LP | 1.57M | 1.12% | $128M | -31% |
| Deerfield Management Company, L.P. | 1.39M | 0.99% | $113M | -12% |
| First Trust Advisors LP | 1.35M | 0.96% | $110M | +807% |
| Driehaus Capital Management LLC | 1.35M | 0.96% | $110M | +13% |
| Jupiter Topco LLC | 1.22M | 0.87% | $99.6M | – |
| Northern Trust Corp | 1.19M | 0.85% | $97.2M | -28% |
| Dimensional Fund Advisors LP | 1.18M | 0.84% | $96.3M | +94% |
| Goldman Sachs Group Inc | 1.15M | 0.82% | $93.7M | -34% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ARWR insiders reported $0 of open-market purchases and $37.3M of sales. 45% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Adeoye Y Olukotun | Director | Sale | 2,000 | $86.96 | $174K | Form 4 |
| Aug 18, 2026 | Michael S Perry | Director | Sale | 11,600 | $87.30 | $1M | Form 4 |
| May 12, 2026 | Hongbo Lu | Director | Sale plan | 2,970 | $76.88 | $228K | Form 4 |
| Apr 23, 2026 | James C Hamilton | Chief Medical Officer | Sale plan | 10,000 | $75.00 | $750K | Form 4 |
| Apr 22, 2026 | Daniel Joseph Apel | CFO | Sale plan | 8,730 | $71.92 | $628K | Form 4 |
| Apr 22, 2026 | Daniel Joseph Apel | CFO | Sale plan | 1,157 | $70.45 | $81.5K | Form 4 |
| Apr 22, 2026 | Daniel Joseph Apel | CFO | Sale plan | 3,208 | $70.11 | $225K | Form 4 |
| Mar 5, 2026 | James C Hamilton | Chief Medical Officer | Sale plan | 10,000 | $64.19 | $642K | Form 4 |
| Jan 5, 2026 | Patrick O'Brien | COO | Sale plan | 46 | $68.00 | $3.1K | Form 4 |
| Jan 5, 2026 | Patrick O'Brien | COO | Sale plan | 4,368 | $61.20 | $267K | Form 4 |
| Jan 5, 2026 | Patrick O'Brien | COO | Sale plan | 6,164 | $62.23 | $384K | Form 4 |
| Jan 5, 2026 | Patrick O'Brien | COO | Sale plan | 13,451 | $62.96 | $847K | Form 4 |
| Jan 5, 2026 | Patrick O'Brien | COO | Sale plan | 11,842 | $63.84 | $756K | Form 4 |
| Jan 5, 2026 | Patrick O'Brien | COO | Sale plan | 2,700 | $64.44 | $174K | Form 4 |
| Jan 5, 2026 | Patrick O'Brien | COO | Sale plan | 900 | $66.01 | $59.4K | Form 4 |
| Jan 5, 2026 | Patrick O'Brien | COO | Sale plan | 313 | $68.00 | $21.3K | Form 4 |
| Jan 5, 2026 | Patrick O'Brien | COO | Sale plan | 600 | $61.12 | $36.7K | Form 4 |
| Jan 5, 2026 | Patrick O'Brien | COO | Sale plan | 900 | $62.25 | $56K | Form 4 |
| Jan 5, 2026 | Patrick O'Brien | COO | Sale plan | 5,873 | $62.91 | $369K | Form 4 |
| Jan 5, 2026 | Patrick O'Brien | COO | Sale plan | 2,336 | $64.04 | $150K | Form 4 |
| Jan 5, 2026 | James C Hamilton | Chief Medical Officer | Sale plan | 4,625 | $61.24 | $283K | Form 4 |
| Jan 5, 2026 | James C Hamilton | Chief Medical Officer | Sale plan | 6,090 | $62.28 | $379K | Form 4 |
| Jan 5, 2026 | James C Hamilton | Chief Medical Officer | Sale plan | 14,792 | $63.01 | $932K | Form 4 |
| Jan 5, 2026 | James C Hamilton | Chief Medical Officer | Sale plan | 309 | $68.00 | $21K | Form 4 |
| Jan 5, 2026 | James C Hamilton | Chief Medical Officer | Sale plan | 1,200 | $64.49 | $77.4K | Form 4 |
| Jan 5, 2026 | James C Hamilton | Chief Medical Officer | Sale plan | 437 | $65.97 | $28.8K | Form 4 |
| Jan 5, 2026 | James C Hamilton | Chief Medical Officer | Sale plan | 12,711 | $63.95 | $813K | Form 4 |
| Jan 2, 2026 | Christopher Richard Anzalone | CEO | Sale plan | 5,771 | $66.39 | $383K | Form 4 |
| Jan 2, 2026 | Christopher Richard Anzalone | CEO | Sale plan | 7,416 | $65.88 | $489K | Form 4 |
| Dec 29, 2025 | Christopher Richard Anzalone | CEO | Sale plan | 16,545 | $68.69 | $1.1M | Form 4 |
| Dec 29, 2025 | Christopher Richard Anzalone | CEO | Sale plan | 35,181 | $69.33 | $2.4M | Form 4 |
| Dec 26, 2025 | Mauro Ferrari | Director | Sale plan | 7,530 | $70.00 | $527K | Form 4 |
| Dec 22, 2025 | Christopher Richard Anzalone | CEO | Sale plan | 2,574 | $68.85 | $177K | Form 4 |
| Dec 22, 2025 | Christopher Richard Anzalone | CEO | Sale plan | 10,012 | $68.33 | $684K | Form 4 |
| Dec 19, 2025 | William D. Waddill | Director | Sale plan | 5,451 | $68.01 | $371K | Form 4 |
| Dec 19, 2025 | William D. Waddill | Director | Sale plan | 2,416 | $66.66 | $161K | Form 4 |
| Dec 19, 2025 | William D. Waddill | Director | Sale plan | 500 | $68.53 | $34.3K | Form 4 |
| Dec 19, 2025 | Victoria Vakiener | Director | Sale plan | 2,799 | $66.63 | $186K | Form 4 |
| Dec 19, 2025 | Victoria Vakiener | Director | Sale plan | 1,960 | $68.39 | $134K | Form 4 |
| Dec 19, 2025 | Victoria Vakiener | Director | Sale plan | 5,281 | $67.97 | $359K | Form 4 |
| Dec 19, 2025 | Christopher Richard Anzalone | CEO | Sale plan | 3,979 | $66.67 | $265K | Form 4 |
| Dec 19, 2025 | Christopher Richard Anzalone | CEO | Sale plan | 8,147 | $68.01 | $554K | Form 4 |
| Dec 19, 2025 | Christopher Richard Anzalone | CEO | Sale plan | 1,319 | $68.48 | $90.3K | Form 4 |
| Dec 19, 2025 | Adeoye Y Olukotun | Director | Sale plan | 3,090 | $66.70 | $206K | Form 4 |
| Dec 19, 2025 | Adeoye Y Olukotun | Director | Sale plan | 6,083 | $68.04 | $414K | Form 4 |
| Dec 19, 2025 | Adeoye Y Olukotun | Director | Sale plan | 827 | $68.48 | $56.6K | Form 4 |
| Dec 17, 2025 | Christopher Richard Anzalone | CEO | Sale | 35,750 | $64.51 | $2.3M | Form 4 |
| Dec 17, 2025 | Christopher Richard Anzalone | CEO | Sale | 982 | $65.53 | $64.4K | Form 4 |
| Dec 17, 2025 | Christopher Richard Anzalone | CEO | Sale | 1,981 | $66.30 | $131K | Form 4 |
| Dec 17, 2025 | Christopher Richard Anzalone | CEO | Sale | 46,287 | $63.55 | $2.9M | Form 4 |
| Dec 16, 2025 | Christopher Richard Anzalone | CEO | Sale | 3,221 | $67.87 | $219K | Form 4 |
| Dec 16, 2025 | Christopher Richard Anzalone | CEO | Sale | 166 | $66.77 | $11.1K | Form 4 |
| Dec 16, 2025 | Christopher Richard Anzalone | CEO | Sale | 1,300 | $65.77 | $85.5K | Form 4 |
| Dec 16, 2025 | Christopher Richard Anzalone | CEO | Sale | 1,000 | $64.96 | $65K | Form 4 |
| Dec 16, 2025 | Christopher Richard Anzalone | CEO | Sale | 8,476 | $62.94 | $533K | Form 4 |
| Dec 16, 2025 | Christopher Richard Anzalone | CEO | Sale | 14,095 | $62.12 | $876K | Form 4 |
| Dec 16, 2025 | Christopher Richard Anzalone | CEO | Sale | 10,963 | $61.25 | $671K | Form 4 |
| Dec 16, 2025 | Christopher Richard Anzalone | CEO | Sale | 8,416 | $60.51 | $509K | Form 4 |
| Dec 16, 2025 | Christopher Richard Anzalone | CEO | Sale | 6,661 | $64.29 | $428K | Form 4 |
| Dec 15, 2025 | Christopher Richard Anzalone | CEO | Sale | 8,147 | $69.96 | $570K | Form 4 |
| Dec 15, 2025 | Christopher Richard Anzalone | CEO | Sale | 21,321 | $69.28 | $1.5M | Form 4 |
| Dec 15, 2025 | Christopher Richard Anzalone | CEO | Sale | 100,532 | $68.67 | $6.9M | Form 4 |
| Dec 5, 2025 | Michael S Perry | Director | Sale | 16,250 | $61.03 | $992K | Form 4 |
| Nov 28, 2025 | Mauro Ferrari | Director | Sale | 8,750 | $56.39 | $493K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Christopher Richard Anzalone | Chief Executive Officer, Director | – | $24M | Jan 2, 2026 |
| James C Hamilton | Chief Medical Officer | – | $3.9M | Apr 23, 2026 |
| Patrick O'Brien | COO | – | $3.1M | Jan 5, 2026 |
| Michael S Perry | Director | – | $2M | Aug 18, 2026 |
| Mauro Ferrari | Director | – | $1M | Dec 26, 2025 |
| Daniel Joseph Apel | Chief Financial Officer | – | $934K | Apr 22, 2026 |
| Adeoye Y Olukotun | Director | – | $851K | Aug 18, 2026 |
| Victoria Vakiener | Director | – | $679K | Dec 19, 2025 |
| William D. Waddill | Director | – | $566K | Dec 19, 2025 |
| Hongbo Lu | Director | – | $228K | May 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ARWR short interest
Moderate short interest. 8.2% of ARWR shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 10%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 11.58M ARWR shares were sold short, 8.2% of the shares outstanding, up 5.7% from the report before. At the average daily volume of 1.36M shares, buying them all back would take about 8.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 11.58M | 8.20% | +6% | 1.36M | 8.5 |
| Oct 15, 2026 | 10.96M | 7.76% | +2% | 2.05M | 5.4 |
| Sep 30, 2026 | 10.76M | 7.62% | +16% | 2.67M | 4.0 |
| Sep 15, 2026 | 9.27M | 6.56% | -2% | 1.80M | 5.2 |
| Aug 31, 2026 | 9.43M | 6.67% | +2% | 1.07M | 8.8 |
| Aug 14, 2026 | 9.21M | 6.52% | -5% | 1.18M | 7.8 |
| Jul 31, 2026 | 9.66M | 6.84% | +0% | 2.51M | 3.9 |
| Jul 15, 2026 | 9.64M | 6.84% | +14% | 1.98M | 4.9 |
| Jun 30, 2026 | 8.43M | 5.99% | -28% | 3.82M | 2.2 |
| Jun 15, 2026 | 11.74M | 8.33% | -5% | 1.43M | 8.2 |
| May 29, 2026 | 12.39M | 8.80% | -4% | 1.49M | 8.3 |
| May 15, 2026 | 12.93M | 9.18% | -0% | 1.84M | 7.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Arrowhead Pharmaceuticals company events
Arrowhead Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026AgreementArrowhead Pharmaceuticals, Inc. and its subsidiary, Arrowhead Madison Inc., as guarantor, refinanced its senior secured term loans under the Existing Financing Agreement (defined below) by entering into an Amended and Restated Financing Agreement with the lenders party thereto and Sixth Street… Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jun 16, 2026LeadershipThe Board of Directors of Arrowhead Pharmaceuticals, Inc. appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 20, 2026VoteReported shareholder vote results. Filing
- Feb 5, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AgreementArrowhead Pharmaceuticals, Inc. issued $700 million of its 0.00% Convertible Senior Notes due 2032. Filing
- Jan 9, 2026AgreementArrowhead Pharmaceuticals, Inc. entered into an underwriting agreement with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein, to issue and sell 3,100,776 shares of the Company’s common stock, $0.001 par value per share, at a public offering… Filing
- Jan 6, 2026AnnouncementThe Company announced interim results from its Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7. Filing
- Nov 25, 2025ResultsReleased financial results. Filing
- Nov 18, 2025AnnouncementArro whead Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved REDEMPLO ® (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Arrowhead Pharmaceuticals financials
Famous investors that hold ARWR
5 of the 50 well-known investors we track reported holding ARWR in their latest 13F filing. The largest position is Ken Fisher's, worth $58.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 893,700 | $58.5M | 0.0% | -7% |
| Israel Englander · Millennium Management | Q3 2026 | 497,587 | $32.6M | 0.0% | +51% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 197,656 | $12.9M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 34,000 | $2.2M | 0.0% | -93% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 10,556 | $691K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ARWR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G/A | 6.6% |
| Nov 5, 2026 | FMR LLC | 13G/A | 6.6% |
Questions about Arrowhead Pharmaceuticals, Inc. (ARWR) stock
Who owns the most ARWR stock?
The largest reported owner of Arrowhead Pharmaceuticals, Inc. (ARWR) is BlackRock, Inc., with 10.5% of the company. In total, 498 funds and institutions reported holding ARWR at the end of Q2 2026, together about 85% of the shares. See the largest owners.
Are ARWR insiders buying or selling?
In the last 12 months, ARWR insiders reported no open-market purchases and 64 sales worth $37.3M. The latest trade was on Aug 18, 2026. See every trade.
What is the short interest in ARWR?
As of Oct 30, 2026, 11.58M ARWR shares were sold short, 8.2% of the shares outstanding, up 5.7% from the report before. At the average daily volume of 1.36M shares, buying them all back would take about 8.5 trading days (days to cover). See the history.
Which famous investors hold ARWR?
5 of the 50 well-known investors we track reported ARWR in their latest 13F filing, including Ken Fisher, Israel Englander, Ken Griffin. The largest position is worth $58.5M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.